Navigation Links
Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

AURORA, Ontario, Sept. 3 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on September 9th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".

For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                        Ian Stone
    Russo Partners LLC                         Russo Partners LLC
    Tel: (212) 845-4226                        Tel: (619) 814-3510
    Email: robert.flamm@russopartnersllc.com   Fax: (619) 955-5318
    www.russopartnersllc.com                   Email:
                                               ian.stone@russopartnersllc.com

This News Release contains certain forward-looking statemen
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
2. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
3. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
4. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
7. Helix BioPharma Announces Q2 2009 Financial Results
8. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
9. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
10. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
11. Helix BioPharma Announces Q1 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
(Date:7/29/2014)... Cat: Can a particle be separated from its properties? ... , published the results of the first Cheshire Cat ... by Chapman University in Orange, CA, and Vienna University ... cat without a grin," thought Alice in Wonderland, "but ... thing I ever saw in my life!" Alice,s surprise ...
(Date:7/29/2014)... 29, 2014 Second generation biofuels are a ... fossil fuels. However, as natural gas is very cheap, this ... are not as valuable as they could be in comparison ... financing projects, has made it difficult for renewable energy developers ... off the ground. For these reasons, certain companies have shifted ...
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... research team co-led by scientists from the J. Craig Venter ... of Maryland School of Medicine, today published the sequence and ... in Nature Biotechnology . Agnes P. Chan, Ph.D., JCVI, ... paper describing the 4.5X coverage of this important oilseed crop. ...
... In Vitro Toxicology Services -- MACCLESFIELD, England, August 20, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... SLN), a leading international RNAi therapeutics company, is pleased ... has announced the grant of an option to Novartis ... commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which ... conducting a Phase II clinical trial of QPI-1002 for ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Cyprotex Adds In Vitro Toxicology Services 2Cyprotex Adds In Vitro Toxicology Services 3Cyprotex Adds In Vitro Toxicology Services 4Cyprotex Adds In Vitro Toxicology Services 5Cyprotex Adds In Vitro Toxicology Services 6Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... Amundsen reached the South Pole in 1911, but new ... any human. , Using data from 16 ice cores ... including the South Pole, a group led by Joe ... Nevada, created the most accurate and precise reconstruction to ... new record, described in an article published today in ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... time when research funding is hard to come by, a ... landed almost $5.5 million in National Institutes of Health highly ... $3.6 million over five years is aimed at determining whether ... of hemophilia A more effective. The second grant worth $2 ...
... will be floating high above the Gulf of Mexico ... DNA analysis instrument developed at Tech that could benefit ... of mechanical engineering, and Collin Tranter, a graduate student ... instrument could be used to monitor the health of ...
... to react when their animals start behaving abnormally. The ... the symptoms are so variable. In some cases the ... which is generally considered to be how most cats spend ... is followed by twitching of facial muscles, chewing and swallowing ...
Cached Biology News:Hemophilia research gets NIH boost to a tune of $5.5 million 2Hemophilia research gets NIH boost to a tune of $5.5 million 3Louisiana Tech University researchers, NASA partner to conduct zero-gravity experiments 2Seizing the opportunity: treating epilepsy in cats 2
Request Info...
... Universal Amplicon Detection Assay (ADA) ... the qualitative detection and quantitation ... in vitro nucleic acid amplification. ... to be used in diagnostic ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... ready-to-use reagents for the isolation of genomic ... for the isolation of genomic DNA from ... for the isolation of genomic DNA from ... can be used for restriction endonuclease digestion ...
Biology Products: